Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Hemispherx Biopharma nets $14.2mm with private sale of shares

Executive Summary

Hemispherx Biopharma (developing infectious disease, cancer, and immunology drug candidates) has netted $14.2mm through the sale of 13.6mm shares at $1.10 each (a 53% premium) to two institutional investors. The backers also received Series A warrants to buy another 6.1mm common shares; the Series I five-year warrants enable the holder to purchase shares for $1.65 each and the Series II warrants are exercisable for 3mm shares within 45 days at $1.10. Rodman & Renshaw was the placement agent.
Deal Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
    • Vaccines
Deal Status
  • Final
Deal Type
  • Financing
    • Private Investment in Public Biotech
    • Private Placement

Related Companies